The DEA’s June 29 Hearing Explained: What Full Cannabis Rescheduling Would Mean for Medical Patients
A federal DEA hearing beginning June 29, 2026 will determine whether all cannabis -- not just state-licensed medical marijuana -- moves from Schedule I to Schedule III. Here's what already changed on April 28, what the hearing is actually deciding, and…
State-licensed medical marijuana reclassified as lower-risk drug by President Trump’s administration
✦ New CED Clinical Relevance #76Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic PolicyMedical…
Colorado business owners say marijuana reclassification could create new opportunities
✦ New CED Clinical Relevance #70Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic PolicyRegulationMedical…
Trump Administration Advances Marijuana Rescheduling | Brownstein
The Trump administration marijuana rescheduling effort marks a pivotal shift in federal cannabis policy. This change could enable more standardized research and insurance coverage. Clinicians should monitor these developments closely for their impact on…
UNLV scientists welcome federal marijuana reclassification – FOX5 Vegas
✦ New CED Clinical Relevance #82High Clinical Relevance Strong evidence or policy relevance with direct clinical implications. ⚒ Cannabis News | CED Clinic PolicyResearchRegulationFederal…
Trump Urges Congress to Address Federal Hemp Product Ban
The federal hemp product ban is creating uncertainty for patient access and clinical care. Trump calls on Congress to fix the law imposing this forthcoming ban. Clinicians must monitor regulatory changes closely to ensure treatment continuity.
How US Marijuana Reclassification Step Will Boost The $47 Billion Cannabis Industry
✦ New CED Clinical Relevance #70Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic PolicyResearchRegulationFederal LawMedical…
DOJ Moves to Loosen Cannabis Restrictions, Signals Shift Toward Rescheduling
The DOJ cannabis policy changes signal a significant shift toward rescheduling cannabis. This move could transform federal research and clinical practice. It promises to reduce legal barriers and improve patient access.
Cotton: Change to marijuana drug classification ‘a step in the wrong direction’
✦ New CED Clinical Relevance #70Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic PolicyRegulationFederal LawPatient…
Local Cannabis CEO Reacts to Federal Marijuana Reclassification
The federal marijuana reclassification impact marks a pivotal shift in cannabis medicine. This change from Schedule I to Schedule II opens new research opportunities while maintaining regulatory oversight. Healthcare providers should monitor evolving…